Evidence map›Paper›PMID 42137586›Full record

ArticleMolecular therapy. Advances2026

High-titer modular retroviral vectors enabled by an antisense cassette design preventing dsRNA formation during virus production.

Romain Vuillefroy de Silly, Patrick Reichenbach, Melita Irving

Erratum issuedAbstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Romain Vuillefroy de SillyLudwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Patrick ReichenbachLudwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
Melita IrvingLudwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retroviral vectors have demonstrated durable safety and therapeutic benefit in the context of cell and gene therapies, but achieving modular, independently controlled gene expression remains a major design challenge. Although antisense cassette architectures enable such regulation, yet they are limited by sharply reduced viral titers caused by double-stranded RNA (dsRNA) formation from convergent transcription during virus production. We developed an antisense cassette strategy that prevents dsRNA generation and preserves high titers. The design incorporates a sense-oriented intron containing an antisense polyadenylation signal into the transfer plasmid, enforcing premature termination of antisense transcription. This intron is subsequently spliced out of the packaged genomic RNA, thereby preventing inverted-promoter-driven dsRNA formation. The approach is compatible with both γ-retroviral and lentiviral vectors, supports diverse promoter combinations, and accommodates external introns as well as microRNA-based short hairpin RNAs for concurrent gene knockdown. As proof of concept, we engineered a dual-cassette vector containing an activation-inducible module paired with a constitutive transgene cassette, achieving robust modular expression alongside high titers. These findings establish a versatile platform enabling independent regulation of multiple genes in retroviral vectors and support the advancement of both basic research and therapeutic applications.

Indexed as

all-in-oneantisensedsRNAintronlentiviruspolyadenylationpromoterretrovirusT cell

Identifiers

PMID42137586
PMCPMC13148933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.